

June 17, 2025



# HeartBeam to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24, 2025

SANTA CLARA, Calif.--(BUSINESS WIRE)-- [HeartBeam, Inc.](#) (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that Robert Eno, Chief Executive Officer, and Timothy Cruickshank, Chief Financial Officer, will present at the iAccess Alpha Virtual Best Ideas Summer Conference on Tuesday, June 24, 2025. Eno and Cruickshank will also host virtual one-on-one meetings with institutional investors during the event.

## **iAccess Alpha Virtual Summer Conference**

Dates: June 24-25, 2025

Location: Virtual

Format: Presentation and Virtual 1x1 Meetings

Attendees: Robert Eno, Chief Executive Officer, and Timothy Cruickshank, Chief Financial Officer

Presentation Time: 2:00 p.m. Eastern Time on June 24

Webcast: <https://www.webcaster4.com/Webcast/Page/3118/52509>

A webcast of the presentation will also be available under the Events section of the Company's investor relations website linked [here](#).

To schedule a one-on-one investor meeting with HeartBeam management, please contact your iAccess Alpha conference representative or email your request to [BEAT@mzgroup.us](mailto:BEAT@mzgroup.us) or call Chris Tyson at (949) 491-8235.

## **About HeartBeam, Inc.**

HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024. The Company holds 20 issued patents related to technology enablement. For additional information, visit [HeartBeam.com](https://HeartBeam.com).

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20250617270939/en/>

**Investor Relations Contact:**

Chris Tyson  
Executive Vice President  
MZ North America  
Direct: 949-491-8235  
[BEAT@mzgroup.us](mailto:BEAT@mzgroup.us)  
[www.mzgroup.us](http://www.mzgroup.us)

**Media Contact:**

[media@heartbeam.com](mailto:media@heartbeam.com)

Source: HeartBeam, Inc.